BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25305450)

  • 1. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer.
    Moon HS; Mantzoros CS
    Endocr Relat Cancer; 2013 Dec; 20(6):849-59. PubMed ID: 24157941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.
    Liu J; Li M; Song B; Jia C; Zhang L; Bai X; Hu W
    Urol Oncol; 2013 Feb; 31(2):264-70. PubMed ID: 21676631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
    Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
    Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
    Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.
    Park WH; Seol JG; Kim ES; Hyun JM; Jung CW; Lee CC; Kim BK; Lee YY
    Cancer Res; 2000 Jun; 60(11):3065-71. PubMed ID: 10850458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
    Malki A; Youssef A
    Oncol Res; 2011; 19(6):275-85. PubMed ID: 21776823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
    Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
    Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
    Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
    Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
    Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
    Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
    Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.